Elsevier’s Oncology Journal Network highlights

Explore the latest breakthroughs shaping cancer research and clinical care with Elsevier’s Oncology Journal Network highlights. Bringing together insights from leading peer-reviewed oncology journals, this collection showcases cutting-edge studies, emerging therapies, and expert perspectives across the cancer continuum—from prevention and diagnosis to treatment and survivorship. Designed for researchers, clinicians, and healthcare professionals, it offers a curated view of high-impact oncology research driving innovation and improving patient outcomes worldwide.

Breast Cancer Awareness Month

• Metastatic breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upopens in new tab/window

• 8th International Consensus Guidelines for the management of advanced breast cancer (ABC8 Guidelines)opens in new tab/window

• Development and validation of a human-supervised AI-augmented living oncology evidence platform: a breast cancer pilot studyopens in new tab/window

• Motherhood’s immune legacy reshapes the breast for lasting cancer defenceopens in new tab/window

• The Role of Immunotherapy in Triple-Negative Breast Cancer (TNBC)opens in new tab/window

• Unlocking the Power of the Homing Phenomenon: Why Breast Conserving Surgery Outshines Mastectomy in Overall Survivalopens in new tab/window

• Harnessing Artificial Intelligence for Precision Diagnosis and Treatment of Triple Negative Breast Canceropens in new tab/window

• CDK4/6 Inhibitors in HER2-positive Metastatic Breast Canceropens in new tab/window

• A Decade of Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Breast Cancer in Spain: A Comprehensive Real-World Data Analysis (2013-2023)opens in new tab/window

• Breast cancer-related lymphedema: A critical review on recent progressopens in new tab/window

• Current approaches to breast reconstruction: A scoping review of outcomes and factors influencing core outcome setsopens in new tab/window

• Association of preoperative and postoperative circulating tumour DNA (ctDNA) with PIK3CA gene mutation with risk of recurrence in patients with non-metastatic breast canceropens in new tab/window

• A systematic review on the management of ductal carcinoma in situ of the breastopens in new tab/window

• Interpectoral nerve blocks may lower postoperative narcotic use after mastectomyopens in new tab/window

• Chemotherapy duration and patient-reported outcomes in HER2-positive early breast cancer: Results from the TRAIN-3 study - ScienceDirectopens in new tab/window

• Chemotherapy type and survival in young BRCA1/2 carriers with HER2-negative early breast cancer - ScienceDirectopens in new tab/window

• Decluttering chemotherapy agents for HER2+early breast cancer: Do we still need carboplatin? - ScienceDirectopens in new tab/window

• Body mass index in postmenopausal women with estrogen receptor-positive, HER2-negative early breast cancer: An exploratory analysis of the LORELEI trial - ScienceDirectopens in new tab/window

• Impact of whole breast irradiation, endocrine therapy or their combination on outcomes of early-stage, luminal A-like, low-risk, breast cancer patients aged 65 years or over: Insights from the EUSOMA database - ScienceDirectopens in new tab/window

• Oncolytic virus-based combination therapy in breast canceropens in new tab/window

• Autophagy-driven regulation of cisplatin response in human cancers: Exploring molecular and cell death dynamicsopens in new tab/window

• Cancer resistance and metastasis are maintained through oxidative phosphorylationopens in new tab/window

• Paclitaxel resistance in breast cancer: Current challenges and recent advanced therapeutic strategiesopens in new tab/window

• CDK4/6 inhibitors and endocrine therapy in the treatment of metastatic breast cancer: A real-world and propensity score-adjusted comparisonopens in new tab/window

• The effects of tumor-derived supernatants (TDS) on cancer cell progression: A review and update on carcinogenesis and immunotherapyopens in new tab/window

• A novel imaging-based approach for large extracellular vesicle detection and prognostic stratification in metastatic breast cancer - ScienceDirectopens in new tab/window

• The impact of liquid biopsy in breast cancer: Redefining the landscape of non-invasive precision oncology - ScienceDirectopens in new tab/window

• Racial and socioeconomic disparities in frailty burden among older women with metastatic breast cancer: A SEER-Medicare analysis - ScienceDirectopens in new tab/window

• A scoping review investigating the influence of comorbidities on the use and outcomes of biological therapies in breast cancer - ScienceDirectopens in new tab/window

• ML: Early Breast Cancer Diagnosisopens in new tab/window

• Diagnosis, investigation, and treatment of occult breast cancer: A case report and systematic review of the literatureopens in new tab/window

• Case report: Heterogeneity in the primary lesions of invasive micropapillary breast carcinomaopens in new tab/window

• Emerging role of necroptosis, pyroptosis, and ferroptosis in breast cancer: New dawn for overcoming therapy resistanceopens in new tab/window

• GRP78 inhibitor YUM70 upregulates 4E-BP1 and suppresses c-MYC expression and viability of oncogenic c-MYC tumorsopens in new tab/window

• Galectin-3 secreted by triple-negative breast cancer cells regulates T cell functionopens in new tab/window

• Anti-PD-1/PD-L1 therapy for colorectal cancer: Clinical implications and future considerationsopens in new tab/window

• Peroxisome proliferator-activated receptors: Key regulators of tumor progression and growthopens in new tab/window

• The prediction of pCR and chemosensitivity for breast cancer patients using DLG3, RADL and Pathomics signatures based on machine learning and deep learningopens in new tab/window

• The role of coenzyme Q10 as a preventive and therapeutic agent for the treatment of cancersopens in new tab/window

• Illuminating the breast cancer survival rates among Southeast Asian women: A systematic review and meta-analysis spanning four decadesopens in new tab/window

• Menin signaling and therapeutic targeting in breast canceropens in new tab/window

• Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast canceropens in new tab/window

• A randomized phase III trial of anthracyclines followed by taxane versus taxane plus carboplatin as (neo)adjuvant therapy in patients with triple-negative breast cancer: KCSG BR 15-1 PEARLY trialopens in new tab/window

• Outcomes of elacestrant in patients with ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer who received prior endocrine therapy and cyclin-dependent kinase inhibitor in a real-world settingopens in new tab/window

• Clinically actionable genomic alterations in breast cancer brain metastasesopens in new tab/window

• Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive HER2-negative breast cancer: safety and patient-reported outcomes from the phase III TROPION-Breast01 studyopens in new tab/window

• Ultrasensitive circulating tumor DNA detection improves prognostication in triple-negative breast cancer postneoadjuvant therapyopens in new tab/window

• Treatment and survival of de novo HER2-positive metastatic breast cancer across regional cancer networks in the Netherlands: a cohort studyopens in new tab/window

• Tolerability, dose modification, and treatment compliance with adjuvant abemaciclib in high-risk early breast cancer: a UK real-world multicentre study (CONCISE)opens in new tab/window

• Safety, treatment delivery, and pathological response before and after pembrolizumab implementation for early ER-negative, HER2-normal breast canceropens in new tab/window

• Artificial intelligence for predicting pathological complete response to neoadjuvant therapy in triple-negative breast cancer: A systematic review and meta-analysisopens in new tab/window

• Translating CLEOPATRA into routine practice: National treatment patterns and survival for patients with HER2-positive metastatic breast canceropens in new tab/window

• Performance of Large Language Models in Ambiguous Treatment Scenarios of Early Breast Canceropens in new tab/window

• Proton Therapy Utilization Among Adult Cancer Patientsopens in new tab/window

• Cardiac Substructure Dose Reduction and Toxicity Risk Assessment: IMPT Versus IMRT for Breast Canceropens in new tab/window

• Optimizing QACT Frequency in Proton Therapy: Analysis of Standard Guidelines Across Treatment Sitesopens in new tab/window

• Breast cancer exosomes: Managing macrophage polarization and immune regulation in the tumor microenvironmentopens in new tab/window

• MicroRNAs: From Bench to Bedside Applications as Breast Cancer Therapeuticsopens in new tab/window

• Advances in the management of metastatic lobular breast cancer: Current evidence and emerging treatmentsopens in new tab/window

• Circular RNAs: Emerging regulators of signaling pathways in epithelial-mesenchymal transition and angiogenesis during breast cancer progressionopens in new tab/window

• A 3-miRNA signature for noninvasive breast cancer detectionopens in new tab/window

• Guidelines for diagnosis and treatment of advanced breast cancer in China (2022 edition)opens in new tab/window

• Cytoskeletal dynamics in breast cancer: mechanistic insights and therapeutic opportunitiesopens in new tab/window

• Do ethnic disparities exist in disease burden and healthcare utilization of male breast cancer? A 9-year cohort study of 9.08 million adults in Chinaopens in new tab/window

• MCLAM: a cost-effective deep learning model for predicting recurrence risk in HR+/HER2− breast cancer—a multi-center study in a Chinese cohortopens in new tab/window

• Genetically predicted inflammatory mediators link mitochondrial function to breast cancer risk: A Mendelian randomization studyopens in new tab/window

• Phytoconstituents as emerging therapeutics for breast cancer: Mechanistic insights and clinical implicationsopens in new tab/window

• Breast cancer risk associated with BRCA1 and BRCA2 pathogenic variants in the Eastern Chinese populationopens in new tab/window

• Nomogram for predicting the risk and prognosis of lung metastasis of four subtypes of breast cancer: A population-based study from SEERopens in new tab/window

• MRI-based habitat analysis for Intratumoral heterogeneity quantification combined with deep learning for HER2 status prediction in breast canceropens in new tab/window

• Prediction of HER-2 expression status in breast cancer based on multi-parameter MRI intratumoral and peritumoral radiomicsopens in new tab/window

• Dentate nucleus signal changes after multiple GBCAs MRI in breast cancer patients: A generalized additive model retrospective studyopens in new tab/window

• APTWI-differential analysis for breast cancer: Association with histopathologic characteristics and early prediction of neoadjuvant chemotherapy responseopens in new tab/window

• Nanomedicines targeting myeloid cells for breast cancer therapyopens in new tab/window

• Intratumor heterogeneity in breast cancer: Tracing its origins and translating findings into clinical practiceopens in new tab/window

• Targeting FOXM1 condensates: A novel strategy for breast cancer treatmentopens in new tab/window

• Comparative analysis of oncological and surgical outcomes of robotic versus conventional mastectomy for breast canceropens in new tab/window

• Profile of surgical complications and complication-led reoperation rates in breast cancer patients who underwent oncoplastic breast surgery with volume displacementsopens in new tab/window

• Breast imaging in focus: A bibliometric overview of visual quality, modality innovations, and diagnostic performanceopens in new tab/window

• A qualitative study of mammography best practice positioning for female body habitus and breast tissue inclusion in Australiaopens in new tab/window

• Australian radiographers' approaches to mammographic imaging of women with cardiac implantable electronic devicesopens in new tab/window

• A Nomogram to Estimate Locoregional Recurrence-Free Survival for Women With T1-2 N0 Breast Cancer Managed With or Without Postmastectomy Radiotherapyopens in new tab/window

• Impact of deep learning on radiologists and radiology residents in detecting breast cancer on CT: a cross-vendor test studyopens in new tab/window

• Artefacts and diagnostic pitfalls in contrast-enhanced mammography: a pictorial reviewopens in new tab/window

• Effects of Aerobic Exercise on Cardiorespiratory Fitness and Cardiovascular Risk Factors in Long-Term Breast Cancer Survivors: A Randomized Controlled Trialopens in new tab/window

• Cardiac Effects of Modern Breast Radiation Therapy in Patients Receiving Systemic Cancer Therapyopens in new tab/window

• Cardiac Safety of Reduced Cardiotoxicity Surveillance During HER2-Targeted Therapyopens in new tab/window

• Real-World Cardiotoxicity of Biosimilar versus Reference Trastuzumab in Early HER2-Positive Breast Canceropens in new tab/window

• Risk Stratification for Trastuzumab-Induced Cardiac Dysfunction and Potential Implications for Surveillanceopens in new tab/window

Lung Cancer Awareness Month

• Real-World Outcomes of Tarlatamab in Small Cell Lung Cancer, Including Patients With Untreated Brain Metastasesopens in new tab/window

• Lung Cancer in Women: The Past, Present, and Futureopens in new tab/window

• Statin Use With Immune Checkpoint Inhibitors and Survival in Nonsmall Cell Lung Canceropens in new tab/window

• Intraoperative Molecular Imaging With Pafolacianine: Histologic Characteristics of Identified Nodulesopens in new tab/window

• Immunotherapy for Early-Stage Non–Small Cell Lung Cancer: A Practical Guide of Current Controversiesopens in new tab/window

• MDT-BRIDGE: Neoadjuvant Durvalumab Plus Chemotherapy Followed by Either Surgery and Adjuvant Durvalumab or Chemoradiotherapy and Consolidation Durvalumab in Resectable or Borderline-resectable Stage IIB–IIIB NSCLCopens in new tab/window

• A Multicenter Randomized Phase III Trial Comparing MET Tyrosine Kinase Inhibitors vs. Immune Checkpoint Inhibitors With or Without Chemotherapy as First-Line Treatment for Patients With Advanced Non–Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutations: JCOG2506 (DECIDE-MET)opens in new tab/window

• A Randomized Phase III Trial of Concurrent Chemoradiotherapy Followed by Durvalumab Consolidation, With or Without Induction Chemo-Immunotherapy, in Patients With Unresectable Locally Advanced Non–Small Cell Lung Cancer: JCOG2510 (PRIME-CRT)opens in new tab/window

• Evaluating the ability of generative AI to standardize TNM staging data in lung canceropens in new tab/window

• Explainable machine learning and feature interpretation to predict survival outcomes in the treatment of lung canceropens in new tab/window

• Pretreatment eosinophilia as a biomarker for adverse outcomes in non-small cell lung cancer patients receiving immune checkpoint inhibitors: A systematic review and meta-analysisopens in new tab/window

• Comparative efficacy of osimertinib with and without radiation therapy in EGFR-mutated nonsmall cell lung cancer with brain metastasesopens in new tab/window

• Female underrepresentation and adverse events reporting biases in lung cancer clinical trials: a systematic review and meta-analysisopens in new tab/window

• The epidemiological landscape of lung cancer: current status, temporal trend and future projections based on the latest estimates from GLOBOCAN 2022opens in new tab/window

• Cancer incidence and mortality in China, 2024opens in new tab/window

• Beyond chemotherapy: The rise of nucleic acid nanoformulations in personalized lung cancer therapyopens in new tab/window

• Inflammatory cytokines and specific factors influencing lung cancer progressionopens in new tab/window

• Targeting tumor-associated neutrophils: A promising strategy in lung cancer immunotherapyopens in new tab/window

• Adoptive cell therapy in lung cancer: progress, challenges, and prospectsopens in new tab/window

• Trends in lung cancer burden, risk factors, and disease projections in China and the United States, 1990–2023opens in new tab/window

• Nanovaccines for lung cancer: Platforms, mechanistic insights, and translational challengesopens in new tab/window

• Definitive Proton Beam Therapy for Second Primary Non–small Cell Lung Cancer After Pneumonectomyopens in new tab/window

• Comprehensive Robustness Evaluation of Proton and Carbon-Ion Plans in Thoracic Cancer Treatmentopens in new tab/window

• Feasibility of Utilizing Spot-Scanning Proton Arc (SPArc) for Whole-Lung Irradiation: A Case Reportopens in new tab/window

• Feasibility and efficacy of hypofractionated proton reirradiation for recurrent lung canceropens in new tab/window

• The management of complex patients with inoperable stage III NSCLC: practical lessons from case-based discussionopens in new tab/window

• Artificial intelligence–based assessment of tumor bed stroma in non–small cell lung cancer after neoadjuvant therapy: Association with pathologic response and survival. A multicenter studyopens in new tab/window

• Characterization of the genomic and transcriptomic landscape of invasive non-mucinous lung adenocarcinoma based on IASLC gradingopens in new tab/window

• Discordance in pleural mesothelioma response classification and modelling of impact on clinical trialsopens in new tab/window

• Change in the incidence of medication-related osteonecrosis of the jaw in lung cancer patients receiving bone modifying agents with immune checkpoint inhibitorsopens in new tab/window

• Synergistic Effect of Linebacker-1 With Radiation Therapy in a Mouse Lung Cancer Modelopens in new tab/window

• Long-term Results of Concurrent Chemoradiotherapy in Elderly Patients with Unresectable Stage III Non-small Cell Lung Canceropens in new tab/window

• Sequencing of Stereotactic Body Radiation Therapy and Chemotherapy in Stage I Small Cell Lung Cancer: Practice Patterns and Outcomesopens in new tab/window

• Heterogeneous Radioimmunotherapy for Bulky Tumors: A Phase 1 Trial for Advanced Non-Small Cell Lung Canceropens in new tab/window

• Evaluation of Cases With Over 10 Years of Follow-up After Stereotactic Body Radiation Therapy for Stage I Lung Canceropens in new tab/window

• Cardiac Substructure Dose Quantification and Optimization in Left-Sided Lung Cancer Radiotherapyopens in new tab/window

• Severe Checkpoint Inhibitor Pneumonitis and Lung Cancer Recurrence After Carbon-ion Radiotherapy in a Patient with Lung Squamous Cell Carcinomaopens in new tab/window

• Longitudinal Plasma Proteomics Reveals an Immuno-thrombotic Signature That Predicts Radiation Pneumonitis in Lung Canceropens in new tab/window

• Comparison of Computed Tomography Ventilation Imaging and Hyperpolarized 3He Magnetic Resonance Imaging in Patients with Lung Canceropens in new tab/window

• High-dose reirradiation of in-field recurrence lung cancer in the THOrax (RETHO): toxicity analysis of a prospective trialopens in new tab/window

• Forecasting Time-Dependent Radiation-Induced Lymphocyte Depletion in a Clinical Trial on Early-Stage Lung Canceropens in new tab/window

• PET-Guided Dose Escalation for Stage III Non-Small Cell Lung Cancer: A Randomized Clinical Trialopens in new tab/window

• PRTN3 promotes IL33/Treg-mediated tumor immunosuppression by enhancing the M2 polarization of tumor-associated macrophages in lung adenocarcinomaopens in new tab/window

• Mobocertinib antagonizes multidrug resistance in ABCB1- and ABCG2-overexpressing cancer cells: In vitro and in vivo studies opens in new tab/window

• Prognostic implication of methylation-based circulating tumor DNA detection prior to surgery in stage I non-small cell lung cancer opens in new tab/window

• Radiomics of metastatic brain tumor as a predictive image biomarker of progression-free survival in patients with non-small-cell lung cancer with brain metastasis receiving tyrosine kinase inhibitors opens in new tab/window

• Systemic immune-inflammation index predicts survival in patients with resected lung invasive mucinous adenocarcinoma✰ opens in new tab/window

• B7-H3/CD276 and small-cell lung cancer: What's new? opens in new tab/windowExpression of Axl in Lung Adenocarcinoma and Correlation with Tumor Progression1opens in new tab/window

• [18F]FDG Uptake and PCNA, Glut-1, and Hexokinase-II Expressions in Cancers and Inflammatory Lesions of the Lung opens in new tab/windowPrognostic Value of Macrophage Phenotypes in Resectable Non–Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry1opens in new tab/window

• Dose-volume comparisons of proton therapy for pencil beam scanning with and without multi-leaf collimator and passive scattering in patients with lung cancer opens in new tab/window

• DIBH reduces right coronary artery and lung radiation dose in right breast cancer loco-regional radiotherapy opens in new tab/window

• Influence of aperture shape controller settings on dose distribution and treatment efficiency in lung stereotactic body radiation therapy with a 10 MV flattening filter-free beam opens in new tab/window

• ChatGPT vs. Gemini: Comparative accuracy and efficiency in Lung-RADS score assignment from radiology reportsopens in new tab/window

• Development of a multi-modal learning-based lymph node metastasis prediction model for lung canceropens in new tab/window

• Diagnostic value of low-dose CT pulmonary angiography combined with iterative reconstruction in suspected pulmonary embolismopens in new tab/window

• ctDNA-based minimal residual disease detection in lung cancer patients treated with curative intended chemoradiotherapy using a clinically transferable approachopens in new tab/window

• Very first real-world data on zongertinib use in non-small cell lung cancer patients with HER2 mutations: A brief report opens in new tab/window

• Assessing Providers’ knowledge about and barriers to lung cancer screening opens in new tab/window

• Early onset venous and arterial thrombosis when combining Osimertinib and Amivantamab in NSCLC: Instructive cases and literature review opens in new tab/window

• Use of anamorelin hydrochloride in a patient with lung cancer-related cachexia undergoing chemoradiotherapy: A case reportopens in new tab/window

• Co-Occurrence of ALK rearrangement and KRAS G12C mutation in NSCLC: Report of two cases opens in new tab/window

• A combined model using pre-treatment CT radiomics and clinicopathological features of non-small cell lung cancer to predict major pathological responses after neoadjuvant chemoimmunotherapy opens in new tab/window

• Current management of uncommon EGFR mutations in non-small cell lung cancer opens in new tab/window

• Targeting MEK in non-small cell lung cancer opens in new tab/window

• A Pooled Analysis of Datopotamab Deruxtecan in Patients With EGFR-Mutated NSCLCopens in new tab/window

• Phase 2 Open-Label Study of Sacituzumab Govitecan as Second-Line Therapy in Patients With Extensive-Stage SCLC: Results From TROPiCS-03opens in new tab/window

• Preventing Infusion-Related Reactions With Intravenous Amivantamab—Results From SKIPPirr, a Phase 2 Study: A Brief Reportopens in new tab/window

• Epidemiology of SCLC in the United States From 2000 to 2019: A Study Utilizing the Surveillance, Epidemiology, and End Results Registryopens in new tab/window

• First-Line Chemo-Immunotherapy in SCLC: Outcomes of a Binational Real-World Studyopens in new tab/window

• Real-World Validity of Tissue-Agnostic Circulating Tumor DNA Response Monitoring in Lung Cancers Treated With Chemotherapy, Immunotherapy, or Targeted Agentsopens in new tab/window

1. ​BRCA1/2 and homologous recombination repair alterations in high- and low-volume metastatic hormone-sensitive prostate cancer: prevalence and impact on outcomesopens in new tab/window

2. Enzalutamide plus Radium-223 in Metastatic Castration-Resistant Prostate Cancer: results of the EORTC 1333/PEACE-3 trial.opens in new tab/window

3. Dostarlimab and niraparib in primary advanced ovarian canceropens in new tab/window

4. Savolitinib plus osimertinib in EGFR-mutated advanced NSCLC with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH studyopens in new tab/window

5. Avelumab + sacituzumab govitecan vs avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysisopens in new tab/window

6. Enfortumab Vedotin Plus Pembrolizumab in Untreated Locally Advanced or Metastatic Urothelial Carcinoma: 2.5-Year Median Follow-Up of the Phase III EV-302/KEYNOTE-A39 Trialopens in new tab/window

7. Ultrasensitive detection and tracking of circulating tumor DNA to predict relapse and survival in patients with locally advanced cervical cancer: phase III CALLA trial analyseopens in new tab/window

Elsevier’s Oncology Journal Network